Publications Publications
Publications

Publications

Filter
Reset
Presentations
ASCO
06.06.2022

A Combined Phase I/II Study of a Novel Bicycle Tumor-targeted Immune Cell Agonist® BT7480 in Patients with Nectin-4 Associated Advanced Malignancies
AACR
04.10.2022

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with...
AACR
04.08.2022

Modeling the cDC1 ex vivo and in vitro: Development and characterization of a conventional dendritic cell culture system for...
AACR
04.08.2022

Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity
AACR
04.08.2022

Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small...
AACR
04.08.2022

Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell...
Microbiology Society Annual Meeting
04.07.2022

Bicycle®: A novel therapeutic modality for SARS-CoV-2
EuroTIDES
11.19.2021

Bicycles, bi-cyclic peptides, novel small molecule delivery systems for RNA therapeutics
First
Previous
Next
Last
Publications
Molecular Cancer Therapeutics
09.16.2022

BT8009; a Nectin-4 targeting Bicycle® Toxin Conjugate for treatment of solid tumors.
Bioconjugate Chemistry
08.02.2022

Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides
Journal of Medicinal Chemistry
07.12.2022

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology
Molecular Cancer Therapeutics
06.08.2022

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Journal for ImmunoTherapy of Cancer
11.02.2021

BT7480, a Novel Fully Synthetic Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Induces Tumor Localized CD137 Agonism
Journal for ImmunoTherapy of Cancer
01.26.2021

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
ACS Infectious Diseases
08.18.2020

An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics
Molecular Cancer Therapeutics
05.12.2020

MMAE delivery using the Bicycle toxin conjugate BT5528
First
Previous
Next
Last
Investor Overview→

Filter

Year
Type

Search